XML 50 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION
The fair value of stock option awards is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. There were no stock options granted in the three month period ended March 30, 2013, or in fiscal year 2012. The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. The performance criteria primarily consist of the achievement of the Company’s annual incentive plan goals. For non-vested restricted common stock awards which solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards which require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed. The Company recognizes compensation costs on a straight-line basis over the requisite service period for time-vested awards.
In 2011, the Company granted 380,000 shares of phantom stock which will be settled in cash at the end of the first 10 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $5.25, prior to September 12, 2016. The vesting of the awards upon achieving a closing stock price of $5.25 for 10 consecutive days is considered a market condition which requires the Company to periodically assess the fair market value of the award, with increases or decrease in the fair market value being reflected in the statement of operations.
A summary of award activity under the stock option plans as of March 30, 2013 and changes during the three month period is as follows (all options were vested as of March 30, 2013):
 
Three months ended March 30, 2013
 
Shares
 
Weighted
Average
Exercise
Price
Balance, December 29, 2012
983,680

 
$
5.26

Options forfeited/canceled
(2,175
)
 
4.23

Options exercised
—

 
—

Balance, all exercisable, March 30, 2013
981,505

 
$
5.26


The following table summarizes information about stock options outstanding and exercisable at March 30, 2013:
 
Options Outstanding and Exercisable
Range of Exercise Prices
Number
Outstanding
and
Exercisable
 
Weighted
Average
Remaining
Contractual
Life (Years)
 
Weighted
Average
Exercise
Price
$ 0.01—$ 3.50
130,000

 
3.00
 
$
3.49

$ 3.75—$ 4.82
213,900

 
2.00
 
3.76

$ 5.00—$ 8.03
537,605

 
1.23
 
5.41

$10.00—$10.00
100,000

 
2.00
 
10.00


981,505

 
1.71
 
$
5.26

Aggregate intrinsic value on March 30, 2013
$
27,750

 

 


The Company has a warrant outstanding to purchase 200,000 shares of the Company’s stock for $3.49 per share.
Non-Vested Restricted Common Stock
A summary of the activity for non-vested restricted common stock awards as of March 30, 2013 and changes during the three month period is presented below:
 
Shares
 
Weighted
Average
Grant
Fair
Value
Balance, December 29, 2012
2,283,048

 
$
4.76

Granted
300,000

 
3.33

Forfeited
(172,000
)
 
4.03

Vested
—

 
—

Balance, March 30, 2013
2,411,048

 
$
4.64


Stock-Based Compensation
The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the three months ended March 30, 2013 and March 31, 2012 (no tax benefits were recognized):
 
Three Months Ended
 
March 30,
2013
 
March 31,
2012
Cost of product revenues
$
54,103

 
$
87,098

Research and development
52,615

 
64,655

Selling, general and administrative
1,399,114

 
867,852

Total
$
1,505,832

 
$
1,019,605


Total unrecognized compensation expense for non-vested restricted common stock as of March 30, 2013 totals $4.4 million and is expected to be recognized over a weighted average period of 2 years.